Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther 2021 06;27(6):490.e1-490.e8

Date

04/07/2021

Pubmed ID

33823167

Pubmed Central ID

PMC8855886

DOI

10.1016/j.jtct.2021.03.006

Scopus ID

2-s2.0-85104620264   4 Citations

Abstract

Consolidation using high-dose chemotherapy with autologous stem cell transplantation (ASCT) is an important component of frontline therapy for children with high-risk neuroblastoma. The optimal preparative regimen is uncertain, although recent data support a role for busulfan/melphalan (BuMel). The Children's Oncology Group (COG) conducted a trial (ANBL12P1) to assess the tolerability and feasibility of BuMel ASCT following a COG induction. Patients with newly diagnosed high-risk neuroblastoma who did not progress during induction therapy and met organ function requirements received i.v. busulfan (every 24 hours for 4 doses based on age and weight) and melphalan (140 mg/m2 for 1 dose), followed by ASCT. Busulfan doses were adjusted to achieve to an average daily area under the curve (AUC) <5500 A?MA ??A minute. The primary endpoint was the occurrence of severe sinusoidal obstruction syndrome (SOS) or grade a?Y4 pulmonary complications within the first 28 days after completion of consolidation therapy. A total of 146 eligible patients were enrolled, of whom 101 underwent BuMel ASCT. The overall incidence of protocol-defined unacceptable toxicity during consolidation was 6.9% (7 of 101). Six patients (5.9%) developed SOS, with 4 (4%) meeting the criteria for severe SOS. An additional 3 patients (3%) experienced grade a?Y4 pulmonary complications during consolidation. The median busulfan AUC was 4558 A?MA ??A min (range, 3462 to 5189 A?MA ??A minute) for patients with SOS and 3512 A?MA ??A min (2360 to 5455 A?MA ??A minute) (PA =A .0142). No patients died during consolidation. From the time of study enrollment, the mean 3-year event-free survival for all 146 eligible patients was 55.6 A? 4.2%, and the mean 3-year overall survival was 74.5 A? 3.7%. The BuMel myeloablative regimen following COG induction was well tolerated, with acceptable pulmonary and hepatic toxicity.

Author List

Granger MM, Naranjo A, Bagatell R, DuBois SG, McCune JS, Tenney SC, Weiss BD, Mosse YP, Asgharzadeh S, Grupp SA, Hogarty MD, Gastier-Foster JM, Mills D, Shulkin BL, Parisi MT, London WB, Han-Chang J, Panoff J, von Allmen D, Jarzembowski JA, Park JR, Yanik GA

Author

Jason A. Jarzembowski MD, PhD Sr Associate Dean, CEO CSG, Professor in the Pathology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Busulfan
Child
Hematopoietic Stem Cell Transplantation
Humans
Induction Chemotherapy
Melphalan
Neuroblastoma
Transplantation, Autologous